Quest Diagnostics MRD minimal residual testing precision biomarker

Enhancing Cancer Treatment Decisions with Ultrasensitive MRD Testing

by Jesus Izaguirre-Carbonell
· Amaze Media Labs

Jul 7^th 2025
19 mins
Quest Diagnostics: The Results Are In

Share This Article

Clips

Summary

Dr. Thomas Slavin breaks down how ultrasensitive MRD testing supports better cancer treatment decisions and enables earlier, more personalized interventions.

Across oncology care, clinicians are facing a growing demand for precision tools that go beyond standard imaging and protein biomarkers. In this episode of Results Are In by Quest Diagnostics, host Jesus Izaguirre-Carbonell welcomes Dr. Thomas P. Slavin Jr., Chief Clinical Officer of Molecular Oncology and Medical Director for Haystack MRD at Quest, for a focused conversation on minimal residual disease (MRD) testing.

Dr. Slavin walks through how ultrasensitive ctDNA detection is changing the game for treatment monitoring, especially in perisurgical and surveillance settings. He explains the science behind circulating tumor DNA, how MRD testing is helping avoid unnecessary chemotherapy, and what makes certain tests stand out in terms of sensitivity and access. The episode also highlights real clinical examples and emerging evidence that show how MRD testing is guiding decisions and reducing overtreatment.

This is a practical listen for clinicians, researchers, and anyone interested in the latest tools transforming cancer management from reactive to proactive.

Click for Source